Coagulation testing

Cardiopulmonary Bypass: Principles and Practice: Third Edition

Volumn , Issue , 2012, Pages 459-471

  Horrow, Jay C ^a   Mueksch, Josef Nile ^a,b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b HAHNEMANN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84926115083     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (84)

1. Koepke JA. Coagulation testing systems. In:Koepke JA, ed. Laboratory hematology. New York:Churchill Livingstone, 1984:1113-1140.
2. van Rijn JLML, Schmidt NA, Rutten WPF. Correction of instrument and reagent based differences in determination of the international normalized ratio (INR) for monitoring anticoagulant therapy. Clin Chem 1989;35:840-843.
3. Miale JB. Hematology, 4th ed. St. Louis:Mosby, 1972:1280.
4. Schmaier AH. Diagnosis and therapy of disseminated intravascular coagulation and activated coagulation. In:Koepke JA, ed. Laboratory hematology. New York:Churchill Livingstone, 1984:631-658.
5. Van Cott EM, Laposata M. Coagulation. In:Jacobs DS, Oxley DK, DeMott WR, eds. The laboratory test handbook, 5th ed. Cleveland:Lexi-Comp, 2001:327-358.
6. Bell WR. Defibrinogenating enzymes. In:Colman RW, Hirsh J, Marder VJ, et al., eds. Hemostasis and thrombosis, 3rd ed. Philadelphia:JB Lippincott Co, 1994:886-900.
7. Despotis GJ, Santoro SA, Spitznagel E, et al. Prospective evaluation and clinical utility of on site monitoring of coagulation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1994;107:271-279.
8. Shore-Lesserson L. Evidence based coagulation monitors:heparin monitoring, thromboelastography, and platelet function. Semin Cardiothorac Vasc Anesth 2005;9:41-52.
9. Ray MJ, Hawson GA, Just SJ, et al. Relationship of platelet aggregation to bleeding after cardiopulmonary bypass. Ann Thorac Surg 1994;57:81-86.
10. Nowak G, Bucha E. Prothrombin conversion intermediate effectively neutralizes toxic levels of hirudin. Thromb Res 1995;80:317-325.
11. Koster A, Loebe M, Hansen R, et al. A quick assay for monitoring recombinant hirudin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II:adaptation of the ecarin clotting time to the ACT II device. J Thorac Cardiovasc Surg 2000;119:1278-1283.
12. Oberhardt BJ, Dermott SC, Taylor M, et al. Dry reagent technology for rapid, convenient measurements of blood coagulation and fibrinolysis. Clin Chem 1991;37:520-526.
13. Hoffmann JJ, Janssen WC. Comparison of three methods for measuring PEG-hirudin in blood. Blood Coagul Fibrinolysis 2001;7:577-581.
14. Koster A, Chew D, Grundel M, et al. Bivalirudin monitored with the ecarin clotting time for anticoagulation during cardiopulmonary bypass. Anesth Analg 2003;96:383-386.
15. Nuttall GA, Oliver WC Jr. Patients with a history of type II heparin-induced thrombocytopenia with thrombosis requiring cardiac surgery with cardiopulmonary bypass:a prospective observational case series. Anesth Analg 2003;96(2):344-350.
16. Koster A, Spiess B. Effectiveness of bivalirudin as a replacement for heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting. Am J Cardiol 2004;93(3):356-359.
17. Despotis GJ, Hogue CW. The relationship between hirudin and activated clotting time:implications for patients with heparin- induced thrombocytopenia undergoing cardiac surgery. Anesth Analg 2001;93(1):28-32.
18. Merry AF, Raudkivi PJ. Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery. Ann Thorac Surg 2004;77(3):925-931.
19. Edwards JT, Hamby JK. Successful use of Argatroban as a heparin substitute during cardiopulmonary bypass:heparin-induced thrombocytopenia in a high-risk cardiac surgical patient. Ann Thorac Surg 2003;75(5):1622-1624.
20. Cannon MA, Butterworth J. Failure of argatroban anticoagulation during off-pump coronary artery bypass surgery. Ann Thorac Surg 2004;77(2):711-713.
21. Hallman SE, Hebbar L. The use of argatroban for carotid endarterectomy in heparin-induced thrombocytopenia. Anesth Analg 2005;100(4):946-948.
22. Fitch JCK, Mirto GP, Geary KLB, et al. Point of care and standard laboratory coagulation testing during cardiovascular surgery. Balancing reliability and timeliness. J Clin Monit Comput 1999;15:197-204.
23. Gilbert HC, Vender JS. The current status of point of care monitoring. Int Anesthesiol Clin 1996;34:243-261.
24. Esposito RA, Culliford AT, Colvin SB, et al. Heparin resistance during cardiopulmonary bypass. The role of heparin pretreatment. J Thorac Cardiovasc Surg 1983;85:346-353.
25. Umlas J, Gauvin G, Taff R. Heparin monitoring and neutralization during cardiopulmonary bypass using a rapid plasma separator and a fluorometric assay. Ann Thorac Surg 1984;37:301-303.
26. Jobes DR, Schwartz AJ, Ellison N, et al. Monitoring heparin anticoagulation and its neutralization. Ann Thorac Surg 1981;31:161-166.
27. Hattersley PG. Activated coagulation time of whole blood. JAMA 1966;196:436-440.
28. Jaberi M, Bell WR, Benson DW. Control of heparin therapy in open heart surgery. J Thorac Cardiovasc Surg 1974;67:133-141.
29. Bjornsson TD, Nash PV. Variability in heparin sensitivity of APTT reagents. Am J Clin Pathol 1986;86:199-204.
30. Gravlee GP, Whitaker CL, Mark LJ, et al. Baseline activated coagulation time should be measured after surgical incision. Anesth Analg 1990;71:549-553.
31. Gravlee GP, Case LD, Angert KC, et al. Variability of the activated coagulation time. Anesth Analg 1988;67:469-472.
32. Bennett JA, Horrow JC. Activated coagulation time:one tube or two? J Cardiothorac Vasc Anesth 1996;10:471-473.
33. Despotis GJ, Alsoufiev AL, Spitznagel E, et al. Response of kaolin ACT to heparin:evaluation with an automated assay and higher heparin doses. Ann Thorac Surg 1996;61:795-799.
34. Green TP, Isham Schopf B, Steinhorn RH, et al. Whole blood activated clotting time in infants during extracorporeal membrane oxygenation. Crit Care Med 1990;18:494-498.
35. Pan C-M, Van Riper DF, Horrow JC, et al. A modified microsample ACT test for heparin monitoring. J Extra Corpor Technol 1996;28:16-20.
36. Wang JS, Lin CY, Hung WT, et al. Monitoring of heparin induced anticoagulation with kaolin activated clotting time in cardiac surgical patients treated with aprotinin. Anesthesiology 1992;77:1080-1084.
37. Dietrich W, Jochum M. Effect of celite and kaolin on activated clotting time in the presence of aprotinin:activated clotting time is reduced by binding of aprotinin to kaolin [brief correspondence]. J Thorac Cardiovasc Surg 1995;109:177-178.
38. Huyzen RJ, Harder MP, Huet RCGG, et al. Alternative perioperative anticoagulation monitoring during cardiopulmonary bypass in aprotinin treated patients. J Cardiothorac Vasc Anesth 1994;8:153-156.
39. Dietrich W, Jochum M. Effect of celite and kaolin on activated clotting time in the presence of aprotinin:activated clotting time is reduced by binding of aprotinin to kaolin. J Thorac Cardiovasc Surg 1995;109:177-178.
40. Cosgrove DM III, Heric B, Lytle BW, et al. Aprotinin therapy for reoperative myocardial revascularization:a placebo-controlled study. Ann Thorac Surg 1992;54:1031-1036.
41. Paul J, Cornillon B, Baguet J, et al. In vivo release of a heparin like factor in dogs during profound hypothermia. J Thorac Cardiovasc Surg 1981;82:45-48.
42. Culliford AT, Gitel SN, Starr N, et al. Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass. Ann Surg 1981;193:105-111.
43. Ammar T, Fisher CF, Sarier K, et al. The effects of thrombocytopenia on the activated coagulation time. Anesth Analg 1996;83:1185-1188.
44. Moorehead MT, Westengard JC, Bull BS. Platelet involvement in the activated coagulation time of heparinized blood. Anesth Analg 1984;63:394-398.
45. Ammar T, Scudder LE, Coller BS. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. Circulation 1997;95:614-617.
46. Kresowik TF, Wakefield TW, Fessler RD II, et al. Anticoagulant effects of protamine sulfate in a canine model. J Surg Res 1988;45:8-14.
47. Dutton DA, Hothersall AP, McLaren AD, et al. Protamine titration after cardiopulmonary bypass. Anaesthesia 1983;38:264-268.
48. Bull MH, Huse WM, Bull BS. Evaluation of tests used to monitor heparin therapy during extra corporeal circulation. Anesthesiology 1975;43:346-353.
49. Gomperts ED, Bethlehem B, Hockley J. The monitoring of heparin activity during extracorporeal circulation. S Afr Med J 1977;51:973-976.
50. Baugh RF. Detection of whole blood coagulation. Am Clin Products Rev 1984;45:38-45.
51. Despotis GJ, Joist JH, Hogue CW Jr, et al. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost 1996;76:902-908.
52. Despotis GJ, Summerfield AL, Joist JH. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 1994;108:1076-1082.
53. Despotis GJ, Levine V, Filos KS, et al. Hemofiltration during cardiopulmonary bypass:the effect on anti Xa and anti IIa heparin activity. Anesth Analg 1997;84:479-483.
54. Anido G, Freeman DJ. Heparin assay and protamine titration. Am J Clin Pathol 1981;76:410-415.
55. Choo IHF, Didisheim P, Doerge ML, et al. Evaluation of a heparin assay method using a fluorogenic synthetic peptide substrate for thrombin. Thromb Res 1982;25:115-123.
56. Gauvin G, Umlas J, Chin N. Measurement of plasma heparin levels using a fluorometric assay. Med Instrum 1983;17:165-168.
57. Savidge GF, Kesteven PJ, Al Hasani SF, et al. Rapid quantitation of plasma heparin and antithrombin III levels for cardiopulmonary bypass monitoring, using fluorometric substrate assays. Thromb Haemost 1983;50:745-748.
58. Huyzen RJ, Harder MP, Gallandat HRCG, et al. Alternative perioperative anticoagulation monitoring during cardiopulmonary bypass in aprotinin treated patients. J Cardiothorac Vasc Anesth 1994;8:153-156.
59. Reich DL, Yanakakis MJ, Vela Cantos FP, et al. Comparison of bedside coagulation monitoring tests with standard laboratory tests in patients after cardiac surgery. Anesth Analg 1993;77:673-679.
60. Bjoraker DG. The thromboelastograph D coagulation analyzer. Anesthesiol Rev 1991;18:34-40.
61. Spiess BD, Tuman RJ, McCarthy RJ, et al. Thromboelastography as an indicator of post cardiopulmonary bypass coagulopathies. J Clin Monit 1987;3:25-30.
62. Howland WS, Schweizer O, Goulp P. Comparison of intraoperative measurements of coagulation. Anesth Analg 1974;53:657-663.
63. Zuckerman L, Cohen E, Vagher JP, et al. Comparison of throm- boelastography with common coagulation tests. Thromb Haemost 1981;46:752-756.
64. von Kaulla K, von Kaulla E, Wasantapruck S, et al. Blood coagulation in uremic patients before and after hemodialysis and transplantation of the kidney. Arch Surg 1966;92:184-191.
65. Nutall GA, Oliver WC, Ereth MH, et al. Coagulation tests predict bleeding after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1997;11:815-823.
66. Nuttall GA, Oliver WC, Santrach PJ, et al. Efficacy of a simple intraoperative transfusion algorithm for nonerythrocyte component utilization after cardiopulmonary bypass. Anesthesiology 2001;94:773-781.
67. Royston D, von Kier S. Reduced haemostatic factor transfusion using heparinase-modified thrombelastography during cardiopulmonary bypass. Br J Anaesth 2001;86:575-578.
68. Shore-Lesserson L, Manspeizer HE, DePerio M, et al. Thrombo- elastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 1999;88:312-319.
69. Shenaq SA, Saleem A. Viscoelastic measurement of clot formation:the Sonoclot. In:Ellison E, Jobes DR, eds. Effective hemostasis in cardiac surgery. Philadelphia:WB Saunders, 1988:183-193.
70. Saleem A, Blifeld C, Saleh SA, et al. Viscoelastic measurement of clot formation:a new test of platelet function. Ann Clin Lab Sci 1983;13:115-124.
71. Samra SK, Harrison RL, Bee DE, et al. A study of aspirin induced changes in bleeding time, platelet aggregation, and Sonoclot coagulation analysis in humans. Ann Clin Lab Sci 1991;21:315-327.
72. Smith JW, Steinhubl SR, Lincoff AM, et al. Rapid platelet function assay:automated and quantitative cartridge-based method. Circulation 1999;99:620-625.
73. Coller BS, Folts JD, Scudder LE, et al. Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein Iib/IIIa receptor in an experimental animal model. Blood 1986;68:783-786.
74. Coller BS, Lang D, Scudder LE. Rapid and simple platelet function assay to assess glycoprotein Iib/IIIa receptor blockade. Circulation 1997;95:860-867.
75. Griffin MJ, Rinder HM, Smith BR, et al. The effects of heparin, protamine, and heparin/protamine reversal on platelet function under conditions of arterial shear stress. Anesth Analg 2001;93:20-27.
76. Wang JS, Lin CY, Hung WT, et al. Thromboelastogram fails to predict postoperative hemorrhage in cardiac patients. Ann Thorac Surg 1992;53:435-439.
77. Dorman BH, Spinale FG, Bailey MK, et al. Identification of patients at risk for excessive blood loss during coronary artery bypass surgery. Thromboelastography versus coagulation screen. Anesth Analg 1993;76:694-700.
78. Ereth MH, Nutall GA, Santrach PJ, et al. The relationship between the platelet activated clotting test (HemoSTATUS) and blood loss after cardiopulmonary bypass. Anesthesiology 1998;88:962-969.
79. Ramsey G, Arvan DA, Stewart S, et al. Do preoperative laboratory tests predict blood transfusion needs in cardiac operations? J Thorac Cardiovasc Surg 1983;85:564-569.
80. Gravlee GP, Arora S, Lavendar SW, et al. Predictive value of blood clotting tests in cardiac surgical patients. Ann Thorac Surg 1994;58:216-221.
81. Tuman KJ, Spiess BD, McCarthy RJ, et al. Comparison of viscoelastic measures of coagulation after cardiopulmonary bypass. Anesth Analg 1989;69:69-75.
82. Wahba A, Rothe G, Lodes H, et al. Predictors of blood loss after coronary artery bypass grafting. J Cardiothorac Vasc Anesth 1997; 11:824-827.
83. Ratnatunga CP, Rees GM, Kovacs IB. Preoperative hemostatic activity and excessive bleeding after cardiopulmonary bypass. Ann Thorac Surg 1991;52:250-257.
84. Greilich PE, Carr ME, Carr SL, et al. Reductions in platelet force development by cardiopulmonary bypass are associated with hemorrhage. Anesth Analg 1995;80:459-465.REFERENCES.